New Data Shows Pacira's EXPAREL Lowers Healthcare Costs, Opioid Use in Outpatient Orthopedic Surgeries
Summary
Pacira BioSciences presented compelling real-world data at the AMCP 2026 Meeting, demonstrating that its flagship non-opioid pain therapy, EXPAREL, is associated with lower total healthcare costs and reduced opioid utilization in outpatient total hip and knee arthroplasty procedures. Specifically, EXPAREL use showed lower total healthcare costs over 3 and 6 months post-surgery and significantly reduced opioid use at 6 months in certain patient populations. These findings provide strong economic and clinical arguments for EXPAREL, reinforcing its value proposition to healthcare providers and payers. This positive data is crucial for driving further market adoption and strengthening Pacira's competitive position in the non-opioid pain management sector, building on the company's recent strong financial performance.
At the time of this announcement, PCRX was trading at $23.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $963.3M. The 52-week trading range was $18.80 to $27.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.